Aphton Announces Presentation at UBS Global Life Sciences Conference.PHILADELPHIA -- Aphton Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :APHT APHT Advance Physical Test ), a biotechnology company focused on the development of immunotherapies for the treatment of cancer, announced today that Patrick Mooney, M.D., Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will present an overview of the company at the upcoming UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Global Life Sciences Conference to be held at the Grand Hyatt in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Dr. Mooney's presentation will be on Tuesday, September 27th at 3:30 p.m. EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT . A live audio webcast of the presentation can be accessed by visiting the UBS conference website at www.ibb.ubs.com. A replay of the presentation will begin 3 hours after the actual presentation and will be available until October 29, 2005. About Aphton Aphton Corporation, headquartered in Philadelphia, Pennsylvania is a clinical stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Aphton's products seek to empower the body's own immune system to fight disease. Through the acquisition of Igeneon AG in March 2005, Aphton acquired late-stage products, IGN101, a cancer vaccine designed to induce an immune response against EpCAM positive tumor cells, and IGN311, a fully humanized antibody against the Lewis Y antigen. Aphton has strategic alliances with Xoma for treating gastrointestinal and other gastrin-sensitive cancers using anti-gastrin monoclonal and other antibodies; Daiichi Pure Chemicals for the development, manufacturing and commercialization of gastrin-related diagnostic kits; and sanofi-aventis for the development and commercialization of Insegia (G17DT immunogen) related to cancers of the gastrointestinal system and other cancers in North America and Europe. Aphton is also currently seeking other partners that will support the further development of Insegia. For more information about Aphton or its programs please visit Aphton's website at www.aphton.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion